APA (7th ed.) Citation

Y, N., M, U., S, K., T, K., Y, S., M, H., . . . T, T. (2025). Authors' Response to "If Status Epilepticus Disappears with Tocilizumab, Paucisymptomatic SARS-CoV-2 Infection Should Be Suspected". Internal medicine (Tokyo, Japan), 64(14), 2262. https://doi.org/10.2169/internalmedicine.5371-25

Chicago Style (17th ed.) Citation

Y, Nakamura, Ueda M, Kodama S, Kimura T, Shirota Y, Hamada M, Ishiura H, Iizuka T, and Toda T. "Authors' Response to "If Status Epilepticus Disappears with Tocilizumab, Paucisymptomatic SARS-CoV-2 Infection Should Be Suspected"." Internal Medicine (Tokyo, Japan) 64, no. 14 (2025): 2262. https://doi.org/10.2169/internalmedicine.5371-25.

MLA (9th ed.) Citation

Y, Nakamura, et al. "Authors' Response to "If Status Epilepticus Disappears with Tocilizumab, Paucisymptomatic SARS-CoV-2 Infection Should Be Suspected"." Internal Medicine (Tokyo, Japan), vol. 64, no. 14, 2025, p. 2262, https://doi.org/10.2169/internalmedicine.5371-25.